LA JOLLA—The Salk Institute and Autobahn Labs, an early-stage drug discovery incubator, will work together to identify and advance promising initial scientific discoveries through the preliminary steps of drug discovery and development. Autobahn Labs will invest up to $5 million per project for Salk discoveries that require access to drug development expertise and state-of-the art capabilities.
LA JOLLA—Scientists from the Salk Institute and the University of Sheffield co-led a study that shows promise for the development of gene therapies to repair hearing loss. In developed countries, roughly 80 percent of deafness cases that occur before a child learns to speak are due to genetic factors. One of these genetic components leads to the absence of the protein EPS8, which coincides with improper development of sensory hair cells in the inner ear. These cells normally have long hair-like structures, called stereocilia, that transduce sound into electrical signals that can be perceived by the brain. In the absence of EPS8, the stereocilia are too short to function, leading to deafness.
LA JOLLA—Salk scientists have uncovered an unexpected molecular target of a common treatment for alopecia, a condition in which a person’s immune system attacks their own hair follicles, causing hair loss. The findings, published in Nature Immunology on June 23, 2022, describe how immune cells called regulatory T cells interact with skin cells using a hormone as a messenger to generate new hair follicles and hair growth.
LA JOLLA—Mammals can’t typically regenerate organs as efficiently as other vertebrates, such as fish and lizards. Now, Salk scientists have found a way to partially reset liver cells to more youthful states—allowing them to heal damaged tissue at a faster rate than previously observed. The results, published in Cell Reports on April 26, 2022, reveal that the use of reprogramming molecules can improve cell growth, leading to better liver tissue regeneration in mice.
LA JOLLA—The Salk Institute announced today that Professor Juan Carlos Izpisua Belmonte, a world-renowned researcher who has pioneered innovations in developmental biology, regenerative medicine and aging research at the Salk Institute, will be closing his Salk laboratory to join Altos Labs, a newly created life sciences company centered on human health research. Izpisua Belmonte, who has been at Salk for nearly thirty years, will depart to lead the San Diego division of Altos Institutes of Science to study cellular rejuvenation programming with the goal of improving human health.
LA JOLLA—Type 1 diabetes, which arises when the pancreas doesn’t create enough insulin to control levels of glucose in the blood, is a disease that currently has no cure and is difficult for most patients to manage. Scientists at the Salk Institute are developing a promising approach for treating it: using stem cells to create insulin-producing cells (called beta cells) that could replace nonfunctional pancreatic cells.
LA JOLLA—One of the many effects of aging is loss of muscle mass, which contributes to disability in older people. To counter this loss, scientists at the Salk Institute are studying ways to accelerate the regeneration of muscle tissue, using a combination of molecular compounds that are commonly used in stem-cell research.
LA JOLLA—The ability to grow the cells of one species within an organism of a different species offers scientists a powerful tool for research and medicine. It’s an approach that could advance our understanding of early human development, disease onset and progression and aging; provide innovative platforms for drug evaluation; and address the critical need for transplantable organs. Yet developing such capabilities has been a formidable challenge.
LA JOLLA—Juan Carlos Izpisua Belmonte, a professor in Salk’s Gene Expression Laboratory, has been named one of TIME magazine’s 50 most influential people in healthcare for his scientific innovations in addressing the shortage of human organs for transplant. The list, which is curated by TIME’s health reporters and editors, recognizes people who changed the state of healthcare in America this year, and bear watching for what they do next.
LA JOLLA—Like an actor who excels at both comedy and drama, proteins also can play multiple roles. Uncovering these varied talents can teach researchers more about the inner workings of cells. It also can yield new discoveries about evolution and how proteins have been conserved across species over hundreds of millions of years.
LA JOLLA—The process by which embryonic stem cells develop into heart cells is a complex process involving the precisely timed activation of several molecular pathways and at least 200 genes. Now, Salk Institute scientists have found a simpler way to go from stem cells to heart cells that involves turning off a single gene.
LA JOLLA—Graying hair, crow’s feet, an injury that’s taking longer to heal than when we were 20—faced with the unmistakable signs of aging, most of us have had a least one fantasy of turning back time. Now, scientists at the Salk Institute have found that intermittent expression of genes normally associated with an embryonic state can reverse the hallmarks of old age.
LA JOLLA—Salk Institute researchers have discovered a holy grail of gene editing—the ability to, for the first time, insert DNA at a target location into the non-dividing cells that make up the majority of adult organs and tissues. The technique, which the team showed was able to partially restore visual responses in blind rodents, will open new avenues for basic research and a variety of treatments, such as for retinal, heart and neurological diseases.
LA JOLLA—Salk Institute scientists have discovered the holy grail of endless youthfulness—at least when it comes to one type of human kidney precursor cell. Previous attempts to maintain cultures of the so-called nephron progenitor cells often failed, as the cells died or gradually lost their developmental potential rather than staying in a more medically useful precursor state.